Selective Activation of Peroxisome Proliferator–Activated Receptor (PPAR)α and PPARγ Induces Neoangiogenesis Through a Vascular Endothelial Growth Factor–Dependent Mechanism
Diabetes2008Vol. 57(5), pp. 1394–1404
Citations Over TimeTop 10% of 2008 papers
Federico Biscetti, Eleonora Gaetani, Andrea Flex, Tamar Aprahamian, Teresa A. Hopkins, Giuseppe Straface, Giovanni Pecorini, Egidio Stigliano, Roy C. Smith, Flavia Angelini, John J. Castellot, Roberto Pola
Abstract
These findings demonstrate that PPAR alpha and PPAR gamma activation stimulates neoangiogenesis through a VEGF-dependent mechanism. Neoangiogenesis is a crucial pathological event in type 2 diabetes. The ability of PPAR alpha and PPAR gamma agonists to induce neoangiogenesis might have important implications for the clinical and therapeutic management of type 2 diabetes.
Related Papers
- Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.(1998)
- → Healing the Diabetic Heart: Modulation of Cardiometabolic Syndrome through Peroxisome Proliferator Activated Receptors (PPARs)(2012)6 cited
- → Recent Progress of Medicinal Chemistry Research on Peroxisome Proliferator-Activated Receptor (PPAR) Ligands for the Treatment of Metabolic Syndrome(2006)
- Problems and prospects of PPAR dual/pan agonists(2008)
- Influence of PPAR Dual Agonists and Cardiovascular Complications(2010)